| Patient | Voltaire |
|---|---|
| Date of birth | 1694-11-21 |
| Identifiers | MRN HR-EN002-SYN-TD; SSN (made up) 000-02-5174 |
| Document date | 2026-11-01 |
| Author | Honorine Delacroix-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for three weeks of visible blood in the urine and difficult urination at 83. Concerns: Blood in the urine and difficulty passing water for three weeks; afraid it is something serious; Wants to finish the play he is staging and to keep writing, and does not want long stays in hospital; Has always taken many remedies of his own choosing and asks for something strong to make him sleep. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter) | One capsule at bedtime | Oral route | 1777-09-01 to 1778-04-06 | stopped | S |
| Tamsulosin 0.4 mg oral capsule, one capsule at bedtime | One capsule 30 minutes after the evening meal | Oral route | 1778-04-06 | active | S |
| Polyethylene glycol 3350, 17 g in a glass of water once daily | 17 g dissolved in water once daily | Oral route | 1776-01-15 | active | S |
| Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 days | One tablet twice daily with food for 7 days | Oral route | 1778-04-20 to 1778-04-26 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day) | Two tablets three times daily; no more than 3 g a day | Oral route | 1778-04-22 | active | S |
| Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensed | Half a tablet every 6 hours as needed; no more than three half tablets a day | Oral route | 1778-04-22 | active | S |
| Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodone | Two tablets at bedtime | Oral route | 1778-04-22 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostril | One spray for suspected overdose; repeat after 2 to 3 minutes if no response | Nasal route | 1778-04-22 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Insertion of a 16 Fr two-way indwelling urethral catheter in the clinic: 520 mL of pink urine drained without clots | 1778-04-06 to 1778-04-06 | completed | S |
| Multiphasic CT urography: 4.2 cm sessile soft-tissue mass of the posterior bladder wall extending to the dome, with wall thickening to 1.8 cm and perivesical fat stranding (suspected extravesical extension); no hydronephrosis; upper tracts clear; prostate about 78 mL with a median lobe; no enlarged pelvic or retroperitoneal nodes; no bone lesions | 1778-04-08 to 1778-04-08 | completed | S |
| CT of the chest with contrast, done with the urography: no lung nodule, mass, or mediastinal lymph node; airways clear; no source for the earlier bleeding from the mouth | 1778-04-08 to 1778-04-08 | completed | S |
| Flexible cystoscopy by urology: solid, sessile, partly necrotic tumor about 4 cm on the posterior wall extending to the dome, with surrounding white keratinizing plaques; trilobar prostatic enlargement with friable surface vessels; catheter replaced | 1778-04-13 to 1778-04-13 | completed | S |
| Transurethral resection of the bladder tumor with examination under anesthesia: a mobile, palpable mass (cT3b); resection to muscle. Pathology: keratinizing squamous cell carcinoma, moderately differentiated, invading the muscularis propria, with lymphovascular invasion; no urothelial carcinoma component and no carcinoma in situ; catheter left for drainage | 1778-04-15 to 1778-04-15 | completed | S |
| Change of the urethral catheter at the sick visit, with a urine culture from the new catheter | 1778-04-20 to 1778-04-20 | completed | S |
| Trial without catheter on tamsulosin: voided 260 mL with a post-void residual of 140 mL | 1778-04-22 to 1778-04-22 | completed | S |
| CT of the bladder for radiotherapy planning | 1778-04-27 to 1778-04-27 | completed | S |
| Hypofractionated external beam radiotherapy to the bladder, 36 Gy in six weekly fractions of 6 Gy, with daily image guidance, by the radiation oncology team; fractions 1 and 2 given by the last visit | 1778-04-29 | in-progress | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1777-10-07 | Influenza vaccine, high dose, 1777-1778 season | completed | S |
| 1776-11-12 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1773-06-03 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 1771-02-18 | Tdap vaccine | completed | S |
| 1776-10-01 | Respiratory syncytial virus vaccine, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 4 November 1723 | Smallpox at 28, with two days of fever and then an eruption, treated with bleeding, emetics, and large amounts of lemonade; out of danger in eleven days | D (CLM-0003) |
| 1769 and throughout his life | Lifelong digestive complaints, colic, and frequent self-treatment with purges and enemas; complaints of the kidneys and bladder; a feeble constitution by his own account | D (CLM-0004) |
| 25 February 1778 | Sudden bleeding from the mouth and nose after a fit of coughing, continuing for several days, six weeks before the index visit; source not established | D (CLM-0006) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died when he was seven; cause not recorded in the cited source | D (CLM-0001) | |
| father | A receiver in the audit office; his health and cause of death are not recorded in the cited sources | D (CLM-0001) |
| Concern | Status | Evidence |
|---|---|---|
| Blood in the urine and difficulty passing water for three weeks; afraid it is something serious | active | S |
| Wants to finish the play he is staging and to keep writing, and does not want long stays in hospital | active | S |
| Has always taken many remedies of his own choosing and asks for something strong to make him sleep | active | S |
Most recent measures: Erythrocytes [#/area] in Urine sediment by Microscopy high power field 75 on 1778-04-06; Leukocytes [#/area] in Urine sediment by Microscopy high power field 60 on 1778-04-20; International Prostate Symptom Score [IPSS] 15 on 1778-05-06; US Urinary bladder Volume post void 120 on 1778-05-06; Hemoglobin [Mass/volume] in Blood 10.8 on 1778-05-06; Leukocytes [#/volume] in Blood by Automated count 6.9 on 1778-05-06; Platelets [#/volume] in Blood by Automated count 231 on 1778-05-06; Sodium [Moles/volume] in Serum or Plasma 138 on 1778-04-06; Potassium [Moles/volume] in Serum or Plasma 4.4 on 1778-05-06; Carbon dioxide, total [Moles/volume] in Serum or Plasma 21 on 1778-04-06; Urea nitrogen [Mass/volume] in Serum or Plasma 22 on 1778-04-13; Creatinine [Mass/volume] in Serum or Plasma 1.2 on 1778-05-06; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M 60 on 1778-05-06; Glucose [Mass/volume] in Serum or Plasma 96 on 1778-04-06; Prostate specific Ag [Mass/volume] in Serum or Plasma 6.4 on 1778-04-06; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 1778-05-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1778-04-28; Total score [Mini-Cog] 4 on 1778-04-28 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluation | resolved | confirmed | R31.0 | S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit. |
| Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheter | active | confirmed | R33.8 | S — Synthetic finding echoing the strangury and catheterization documented in his last weeks. |
| Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier) | resolved | confirmed | N17.9 | S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia. |
| Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decision | active | confirmed | N40.1 | S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012). |
| Squamous cell carcinoma of the bladder, keratinizing, posterior wall extending to the dome, muscle-invasive with extravesical extension (clinical stage cT3b N0 M0, stage IIIA), pure squamous histology without a urothelial component; treated with palliative-intent hypofractionated radiotherapy by shared decision | active | confirmed | C67.4 | S — Synthetic modern diagnosis confirmed by resection pathology. His bladder disease at autopsy is documented (D); calling it squamous cell carcinoma is a 2025 retrospective interpretation (R, disputed). |
| Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemas | active | confirmed | K59.09 | S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made. |
| Febrile catheter-associated urinary tract infection with Escherichia coli, five days after bladder tumor resection; treated with cefpodoxime and a catheter change; resolved | resolved | confirmed | T83.511A | S — Synthetic intercurrent infection; it echoes, without asserting, the infected urine described in his last weeks (CLM-0009). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1778-04-06 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 75 | /[HPF] | 0 to 2 per high-power field; 3 or more is microhematuria (AUA/SUFU) | High | S |
| 1778-04-06 | Leukocytes [#/area] in Urine sediment by Microscopy high power field | 8 | /[HPF] | <=5 /[HPF] | High | S |
| 1778-04-06 | International Prostate Symptom Score [IPSS] | 22 | {score} | S | ||
| 1778-04-06 | US Urinary bladder Volume post void | 460 | mL | Below 100 mL; 300 mL or more suggests chronic retention | High | S |
| 1778-04-06 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1778-04-06 | Leukocytes [#/volume] in Blood by Automated count | 7.8 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1778-04-06 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1778-04-06 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1778-04-06 | Potassium [Moles/volume] in Serum or Plasma | 5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1778-04-06 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 21 | mmol/L | 22-29 mmol/L | Low | S |
| 1778-04-06 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 | mg/dL | 8-24 mg/dL | High | S |
| 1778-04-06 | Creatinine [Mass/volume] in Serum or Plasma | 1.68 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1778-04-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M | 40 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1778-04-06 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1778-04-06 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.4 | ng/mL | <=4 ng/mL | High | S |
| 1778-04-13 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1778-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1778-04-13 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 8-24 mg/dL | Normal | S |
| 1778-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.24 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1778-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M | 58 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1778-04-20 | Leukocytes [#/area] in Urine sediment by Microscopy high power field | 60 | /[HPF] | <=5 /[HPF] | High | S |
| 1778-04-20 | Leukocytes [#/volume] in Blood by Automated count | 12.6 | 10*3/uL | 3.4-9.6 10*3/uL | High | S |
| 1778-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 1.34 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1778-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M | 53 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1778-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1778-04-22 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1778-04-22 | Leukocytes [#/volume] in Blood by Automated count | 8.2 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1778-04-22 | Platelets [#/volume] in Blood by Automated count | 254 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1778-04-22 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1778-04-22 | Creatinine [Mass/volume] in Serum or Plasma | 1.22 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1778-04-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M | 59 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1778-04-22 | US Urinary bladder Volume post void | 140 | mL | Below 100 mL; 300 mL or more suggests chronic retention | High | S |
| 1778-04-22 | International Prostate Symptom Score [IPSS] | 14 | {score} | S | ||
| 1778-04-22 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S | ||
| 1778-04-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1778-04-28 | Total score [Mini-Cog] | 4 | {score} | S | ||
| 1778-05-06 | Hemoglobin [Mass/volume] in Blood | 10.8 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1778-05-06 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1778-05-06 | Platelets [#/volume] in Blood by Automated count | 231 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1778-05-06 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1778-05-06 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1778-05-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1773)/1.73 sq M | 60 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1778-05-06 | US Urinary bladder Volume post void | 120 | mL | Below 100 mL; 300 mL or more suggests chronic retention | High | S |
| 1778-05-06 | International Prostate Symptom Score [IPSS] | 15 | {score} | S | ||
| 1778-05-06 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1778-04-06 | Body height | 170 | cm | S |
| 1778-04-06 | Body weight | 54.2 | kg | S |
| 1778-04-06 | Body mass index (BMI) [Ratio] | 18.8 | kg/m2 | S |
| 1778-04-06 | Systolic blood pressure | 138 | mm[Hg] | S |
| 1778-04-06 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1778-04-06 | Heart rate | 84 | /min | S |
| 1778-04-06 | Respiratory rate | 16 | /min | S |
| 1778-04-06 | Body temperature | 36.7 | Cel | S |
| 1778-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1778-04-13 | Body height | 170 | cm | S |
| 1778-04-13 | Body weight | 54 | kg | S |
| 1778-04-13 | Body mass index (BMI) [Ratio] | 18.7 | kg/m2 | S |
| 1778-04-13 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1778-04-13 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1778-04-13 | Heart rate | 80 | /min | S |
| 1778-04-13 | Respiratory rate | 16 | /min | S |
| 1778-04-13 | Body temperature | 36.6 | Cel | S |
| 1778-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1778-04-20 | Body height | 170 | cm | S |
| 1778-04-20 | Body weight | 53.6 | kg | S |
| 1778-04-20 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 1778-04-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1778-04-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1778-04-20 | Heart rate | 98 | /min | S |
| 1778-04-20 | Respiratory rate | 18 | /min | S |
| 1778-04-20 | Body temperature | 38.4 | Cel | S |
| 1778-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1778-04-22 | Body height | 170 | cm | S |
| 1778-04-22 | Body weight | 53.4 | kg | S |
| 1778-04-22 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 1778-04-22 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1778-04-22 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1778-04-22 | Heart rate | 82 | /min | S |
| 1778-04-22 | Respiratory rate | 16 | /min | S |
| 1778-04-22 | Body temperature | 36.9 | Cel | S |
| 1778-04-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1778-04-28 | Body height | 170 | cm | S |
| 1778-04-28 | Body weight | 53.5 | kg | S |
| 1778-04-28 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 1778-04-28 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1778-04-28 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1778-04-28 | Heart rate | 78 | /min | S |
| 1778-04-28 | Respiratory rate | 16 | /min | S |
| 1778-04-28 | Body temperature | 36.6 | Cel | S |
| 1778-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1778-05-06 | Body height | 170 | cm | S |
| 1778-05-06 | Body weight | 53 | kg | S |
| 1778-05-06 | Body mass index (BMI) [Ratio] | 18.3 | kg/m2 | S |
| 1778-05-06 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1778-05-06 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1778-05-06 | Heart rate | 80 | /min | S |
| 1778-05-06 | Respiratory rate | 16 | /min | S |
| 1778-05-06 | Body temperature | 36.7 | Cel | S |
| 1778-05-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1778-04-06 | Primary care visit for three weeks of visible blood in the urine and difficult urination at 83 | finished | S |
| 1778-04-13 | One-week review of CT urography and kidney function; urology consultation with office cystoscopy | finished | S |
| 1778-04-22 | Review of resection pathology, diagnosis, geriatric assessment, trial without catheter, and shared decision on treatment | finished | S |
| 1778-05-06 | Two-week review during weekly radiotherapy: symptoms, kidney function, voiding, and opioid safety | finished | S |
| 1778-04-20 | Same-day sick visit for fever with a catheter after bladder tumor resection | finished | S |
| 1778-04-28 | Subsequent annual wellness visit at 83 | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Hematuria evaluation: urinalysis with microscopy, urine culture, urine cytology, blood count, kidney function, multiphasic CT urography with CT of the chest, and cystoscopy | completed | GL-AUA-MH-2025, GL-CMID-2026 | S |
| Urology consultation for gross hematuria with chronic retention: cystoscopy, resection if a tumor is found, the voiding trial, and the meaning of the PSA | completed | GL-AUA-MH-2025, GL-CMID-2026, GL-AUA-BPH-2023 | S |
| Retention: indwelling catheter now, tamsulosin at bedtime, catheter care teaching, then a trial without catheter with a bladder scan; IPSS and post-void residual at each visit | completed | GL-AUA-BPH-2023, GL-IDSA-CAUTI-2009, GL-CMID-2026 | S |
| Medication review: stop the diphenhydramine sleep aid and the over-the-counter sodium phosphate enemas; keep polyethylene glycol; cut coffee to two cups a day, none after noon; sleep advice without sedatives | completed | GL-ASCO-GERI-2018, GL-BEERS-2023 | S |
| Shared decision on PSA testing: drawn before the catheter to interpret an enlarged, firm prostate, with the understanding that a raised value at 83 would lead to biopsy only if it would change treatment | completed | GL-AUA-BPH-2023, GL-USPSTF-PSA-2018 | S |
| Transurethral resection of the bladder tumor with examination under anesthesia, for diagnosis and staging | completed | GL-NCCN-BLADDER-2026, GL-AUA-MIBC-2024, GL-EAU-MIBC-2026, GL-CMID-2026 | S |
| Geriatric assessment (G8 screen, function, falls, cognition, mood, nutrition, social support, and medicines) before choosing cancer treatment | completed | GL-ASCO-GERI-2018, GL-BEERS-2023, GL-NCCN-BLADDER-2026 | S |
| Shared decision on treatment of muscle-invasive squamous cell carcinoma: radical cystectomy, trimodality bladder preservation, palliative hypofractionated radiotherapy, or symptom care alone; he chose weekly radiotherapy, 36 Gy in six fractions, given by the radiation oncology team | completed | GL-NCCN-BLADDER-2026, GL-AUA-MIBC-2024, GL-EAU-MIBC-2026, GL-CMID-2026, GL-HYBRID-2017 | S |
| Pain plan: scheduled acetaminophen; oxycodone 2.5 mg only if needed, no more than three doses a day, 15 tablets at a time from one prescriber; naloxone nasal spray; senna; the state prescription monitoring program checked; no alcohol, sleep aids, or anyone else's opium-based remedies; doses kept in a locked box; review within two weeks | completed | GL-CDC-OPIOID-2022, GL-BEERS-2023 | S |
| Palliative care team joins his care alongside radiotherapy for symptom control, goals of care, and support at home | completed | GL-NCCN-BLADDER-2026, GL-ASCO-GERI-2018 | S |
| Advance care planning: name a health care agent and complete a portable medical order reflecting his wishes | completed | GL-PREV-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Find the cause of the bleeding within three weeks | 1778-04-22 | completed | CT urography in two days, cystoscopy in one week, resection in nine days; pathology reviewed at sixteen days | S |
| Relieve the retention and recover kidney function | 1778-04-22 | completed | Creatinine 1.68 to 1.22 mg/dL; voiding after the trial without catheter with a residual of 140 mL | S |
| Treatment that controls bleeding and local symptoms while keeping him at home and writing | 1778-05-27 | active | Weekly radiotherapy under way; no clots or retention since the resection; writing most days | S |
| Pain at or below 3 of 10 without sedation, falls, or constipation | 1778-05-27 | active | Pain 2 of 10 on scheduled acetaminophen and about one half tablet of oxycodone a day; no sedation | S |
| A written plan for future care, with a named health care agent | 1778-04-28 | completed | Health care agent named and a portable medical order completed at the wellness visit | S |